Modern prescription combinations

DXM FAQ 1997: selective audit by topic

How indications for DXM combinations developed and what they cover.

Therapeutic uses: specific combinations

The modern picture includes a prescription combination of DXM and bupropion: Auvelity has a US indication for major depressive disorder in adults. In 2026, the FDA added agitation associated with dementia due to Alzheimer’s disease.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: The current label describes a specific combination product and clinical studies supporting its indications. Bupropion increases DXM exposure through CYP2D6 inhibition.

Limits of the conclusion: The conclusion concerns the product composition and indications studied. The label describes DXM’s therapeutic mechanism as unclear.

Sources: Auvelity — current label FDA — new Auvelity indication

Historical paraphrase · FAQ 4.0 · 1997 · §6.8 The FAQ is skeptical about dissociative substances as treatments for depression.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.8 · Kicking the DXM Habit: What to Do If You are Addicted

Sources for this topic
  1. Auvelity — current label — Official label

    Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.

  2. FDA — new Auvelity indication — Official announcement

    The official FDA announcement of 30 April 2026 was read.

All update topics · Review coverage

Reference

Open the source and related combinations →